For diabetes patients, A1c reductions of approximately 1.0-1.5 percentage points are common with GLP-1 receptor agonists, while tirzepatide has shown reductions of up to 2.0-2.3 percentage points in clinical trials
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats
However, in metabolic peptide research, glucagon receptor activity is also being explored for its potential involvement in increased caloric expenditure, fat oxidation pathways, thermogenic signaling, and energy utilization
Contrave (naltrexone/bupropion) Approved - An oral medication combining an opioid antagonist and an antidepressant
Lancet 394 , 131138 (2019)
Please visit Ozempic.com or Wegovy.com for a full list of important safety information for these medications